MGI: Pioneering Life Science Innovation Through ESHG Partnerships

Strengthening RNA Sequencing Protocols with Alithea Genomics Collaboration

MGI: Pioneering Life Science Innovation Through ESHG Partnerships Strengthening RNA Sequencing Protocols with Alithea Genomics Collaboration Glasgow, UK, 14 June 2023 – MGI Tech Co., Ltd. ("MGI"), a global leader in life science technology, unveiled significant partnerships at the ESHG Conference in Glasgow. These collaborations underscore MGI's strategic focus on the European life sciences market and its dedication to advancing innovation in sequencing and automation technologies.

MGI: A Leading Supplier of Gene Sequencing Platforms

During the Corporate Satellite meeting, MGI, renowned for its gene sequencing platforms and sample preparation systems, announced its partnership with Sistemas Genomicos. Alejandra Pérez presented impressive results of the CE-IVD Whole Exome Sequencing solution on the MGI platform. Nik Matthews, a respected scientific expert from Imperial College London, provided insights into the workflow of the new NEB library preparation solution for MGI, highlighting its benefits for DNBSEQ users. Prof. Yannis Pitsiladis presented his multi-omic approach to combating drug abuse in sports using the DNBSEQ platform, emphasizing its potential and versatility.

MGI's Commitment to Life Science Innovation

"We are excited to showcase our latest achievements at the ESHG Conference, reflecting significant advancements in life science innovation. These partnerships and collaborations exemplify MGI's commitment to driving scientific progress and transforming healthcare,” stated Dr. Yong Hou, General Manager of MGI Europe and Africa.

"By leveraging cutting-edge technologies and fostering collaborations, we aim to revolutionize genomics research, empower scientists and clinical labs with state-of-the-art solutions. This reaffirms MGI's position as a leader in the industry and highlights our dedication to pushing the boundaries of what is possible in the field of life sciences."

MGI and Alithea Genomics: A Strategic Partnership

In line with MGI's commitment to innovation in RNA sequencing, the company also signed a strategic partnership with Alithea Genomics. This Swiss company, known for challenging the status quo in bulk RNA sequencing, has developed extraction-free and massively multiplexed RNA-seq library preparation solutions with native MGI compatibility.

The event attracted a diverse audience of researchers, both in person and online, along with senior management members from MGI. The platform provided MGI with a great opportunity to strengthen its commitment to enhancing innovation through local partnerships in Europe, a market MGI considers to be a key one because of its world-class academic and public research funding, extensive regulatory landscape, and wide range of clinical applications.

For more information about MGI, please visit: MGI Tech

Note: Availability of StandardMPS and CoolMPS sequencing reagents, and sequencers for use with such reagents may vary by region. Products are provided for Research Use Only. Not for use in diagnostic procedures (except as specifically noted).

About MGI

MGI Tech Co., Ltd. (MGI) is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on research & development, production, and sales of sequencing instruments***, reagents***, and related products to support life science research, agriculture, precision medicine, and healthcare. MGI's mission is to develop and promote advanced life science tools for future healthcare. As of December 2021, MGI has a footprint that spans across more than 80 countries and regions, serves over 1,300 international users, and employs more than 2,050 professionals globally, around 35% of which are R&D personnel. For more information, please visit the mgi-tech.eu or connect on Twitter, LinkedIn, or YouTube.    or connect on Twitter, LinkedIn, or YouTube.